Women-initiated HIV – 1 prevention products are key to reducing women’s HIV-1 risk. Clinical trials of vaginal microbicides have shown limited to no efficacy in intention-to-treat (ITT) analyses. It is hypothesized that these negative results are partly due to efficacy dilution.
Methods
We developed a microsimulation model of MTN-020/ASPIRE, a phase 3 trial that evaluated monthly use of a dapivirine vaginal ring for HIV-1 prevention. We evaluated four sources of efficacy dilution: trial-level factors: (i) an imbalance in the number of monthly sex acts between study arms and (ii) heterogeneity in risk emergent over time; and individual-level factors: (iii) product non-adherence and (iv) receptive anal intercourse.
Results
Assuming 70% per-vaginal exposure efficacy (consistent with the ITT estimate of 27%), heterogeneity in risk accounted for the largest proportion of efficacy dilution, at 42% (90% CrI: 38, 45), followed by non-adherence (33%; 90% CrI: 27, 39), an imbalance in arms (18%; 90% CrI: 16, 21) and lastly, anal intercourse with less than 10% of efficacy dilution.
Conclusion
Our results suggest that heterogeneity in risk was the most important source of efficacy dilution in the ASPIRE trial. Future trials of HIV-1 prevention products for women should consider alternative trial designs and analytic approaches that minimize bias introduced by heterogeneity in risk.
AIDSinfo. Joint united nations programme on HIV/AIDS (UNAIDS). Geneva, Switzerland: AIDSinfo. https://aidsinfo.unaids.org (2019, accessed 28 October 2019).
2.
CelumCLDelany-MoretlweSMcConnellM, et al.Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc2015; 18(4 Suppl 3): 20227.
3.
MontgomeryETvan der StratenAStadlerJ, et al.Male partner influence on women’s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of understanding. AIDS Behav2015; 19(5): 784–793.
4.
Abdool KarimQAbdool KarimSSFrohlichJA, et al.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010; 329(5996): 1168–1174.
5.
BaetenJMPalanee-PhillipsTBrownER, et al.Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med2016; 375(22): 2121–2132.
6.
NelAvan NiekerkNKapigaS, et al.Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med2016; 375(22): 2133–2143.
7.
MarrazzoJMRamjeeGRichardsonBA, et al.Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med2015; 372(6): 509–518.
8.
LagakosSWGableAR. Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med2008; 358(15): 1543–1545.
9.
SuccopSMMacQueenKMvan LoggerenbergF, et al.Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care2014; 26(12): 1521–1525.
10.
van der StratenAMontgomeryETHartmannM, et al.Methodological lessons from clinical trials and the future of microbicide research. Curr HIV AIDS Rep2013; 10(1): 89–102.
11.
WoodsongCMacQueenKAmicoKR, et al.Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc2013; 16(1): 18505.
12.
TrussellJDominikR. Will microbicide trials yield unbiased estimates of microbicide efficacy?Contraception2005; 72(6): 408–413.
13.
SeidmanDWeberSAaronE. Dapivirine vaginal ring for HIV-1 prevention. N Engl J Med2017; 376(10): 995.
14.
McGowanITaylorDJ. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies. Sex Transm Dis2010; 37(6): 361–364.
15.
PeeblesKvan der StratenAPalanee-PhillipsT, et al.Brief report: brief report: dapivirine ring HIV-1 prevention effectiveness for women engaged in vaginal and anal intercourse: insights from mathematical modeling. J Acquir Immune Defic Syndr, 2023; 92(2): 122–126. DOI: 10.1097/QAI.0000000000003110.
16.
AuvertBSittaRZarcaK, et al.The effect of heterogeneity on HIV prevention trials. Clin Trials2011; 8(2): 144–154.
17.
Domínguez IslasCPBrownER. Crossover and repeated randomization in event driven trials for HIV prevention: addressing the impact of heterogeneity in risk in the trial design. Stat Commun Infect Dis2019; 11(1): 20190009.
18.
GoldsteinEPitzerVEO’HaganJJ, et al.Temporally varying relative risks for infectious diseases: implications for infectious Disease control. Epidemiology2017; 28(1): 136–144.
19.
HernánMA. The hazards of hazard ratios. Epidemiology2010; 21(1): 13–15.
20.
MoolgavkarSHChangETWatsonHN, et al.An assessment of the cox proportional hazards regression model for epidemiologic studies. Risk Anal2018; 38(4): 777–794.
21.
HernanMA. The hazards of hazard ratios. Epidemiology2010; 21(1): 13–15.
22.
O’HaganJJHernanMAWalenskyRP, et al.Apparent declining efficacy in randomized trials: examples of the Thai RV144 HIV vaccine and South African CAPRISA 004 microbicide trials. AIDS2012; 26(2): 123–126.
BrownERHendrixCWVan der StratenA, et al.Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc2020; 23(11): e25634.
25.
DubyZHartmannMMahakaI, et al.Lost in translation: language, terminology, and understanding of penile-anal intercourse in an HIV prevention trial in South Africa, Uganda, and Zimbabwe. J Sex Res2016; 53(9): 1096.
26.
R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
27.
MasseBRBoilyMCDimitrovD, et al.Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg Themes Epidemiol2009; 6: 5.
28.
BalkusJEBrownEPalaneeT, et al.An empiric HIV risk scoring tool to predict HIV-1 acquisition in african women. J Acquir Immune Defic Syndr2016; 72(3): 333–343.
29.
BalkusJEBrownERPalanee-PhillipsT, et al.Performance of a validated risk score to predict HIV-1 acquisition among african women participating in a trial of the dapivirine vaginal ring. J Acquir Immune Defic Syndr2018; 77(1): e8–e10.
30.
Delany-MoretlweSLombardCBaronD, et al.Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis2018; 18(11): 1241–1250.
31.
Abdool KarimSSPassmoreJASBaxterC. The microbiome and HIV prevention strategies in women. Curr Opin HIV AIDS2018; 13(1): 81–87.
32.
MillerLMorarNKapigaS, et al.Women design their own vaginal microbicide trial: suggestions on how to improve adherence from former participants of HIV prevention trials. PLoS One2021; 16(1): e0244652.
33.
WeissHAWasserheitJNBarnabasRV, et al.Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol2008; 5: 8.
